ropivacaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| local anaesthetics | 2403 | 84057-95-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 53.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.62 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.75 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 24, 1996 | FDA | FRESENIUS KABI USA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Maternal exposure during delivery | 179.35 | 36.06 | 36 | 3838 | 1464 | 63483684 |
| Anaesthetic complication | 158.37 | 36.06 | 34 | 3840 | 1926 | 63483222 |
| Anaphylactic shock | 129.05 | 36.06 | 50 | 3824 | 23583 | 63461565 |
| Peripheral nerve injury | 118.47 | 36.06 | 21 | 3853 | 430 | 63484718 |
| Generalised tonic-clonic seizure | 115.77 | 36.06 | 49 | 3825 | 28967 | 63456181 |
| Cauda equina syndrome | 113.52 | 36.06 | 23 | 3851 | 979 | 63484169 |
| Exposure during pregnancy | 100.67 | 36.06 | 80 | 3794 | 155467 | 63329681 |
| Cardiac arrest | 92.61 | 36.06 | 62 | 3812 | 92483 | 63392665 |
| Hypotension | 89.74 | 36.06 | 96 | 3778 | 272508 | 63212640 |
| Maternal exposure during pregnancy | 87.82 | 36.06 | 86 | 3788 | 219976 | 63265172 |
| Myoclonus | 84.55 | 36.06 | 33 | 3841 | 15835 | 63469313 |
| Local anaesthetic systemic toxicity | 80.61 | 36.06 | 17 | 3857 | 882 | 63484266 |
| Neurotoxicity | 75.49 | 36.06 | 31 | 3843 | 16959 | 63468189 |
| Toxicity to various agents | 70.78 | 36.06 | 81 | 3793 | 247169 | 63237979 |
| Phrenic nerve paralysis | 64.09 | 36.06 | 11 | 3863 | 185 | 63484963 |
| Tracheal deviation | 59.22 | 36.06 | 10 | 3864 | 152 | 63484996 |
| Seizure | 58.78 | 36.06 | 55 | 3819 | 132579 | 63352569 |
| Motor dysfunction | 55.97 | 36.06 | 22 | 3852 | 10739 | 63474409 |
| Spinal epidural haemorrhage | 55.83 | 36.06 | 9 | 3865 | 101 | 63485047 |
| Monoplegia | 54.72 | 36.06 | 16 | 3858 | 3185 | 63481963 |
| Respiratory depression | 54.11 | 36.06 | 23 | 3851 | 13692 | 63471456 |
| Vitamin K deficiency | 49.24 | 36.06 | 10 | 3864 | 430 | 63484718 |
| Nerve block | 48.91 | 36.06 | 11 | 3863 | 771 | 63484377 |
| Oliguria | 48.72 | 36.06 | 19 | 3855 | 9082 | 63476066 |
| Paraplegia | 48.53 | 36.06 | 14 | 3860 | 2658 | 63482490 |
| Premature delivery | 47.34 | 36.06 | 27 | 3847 | 30254 | 63454894 |
| Caesarean section | 43.22 | 36.06 | 21 | 3853 | 17011 | 63468137 |
| Hypoaesthesia | 42.82 | 36.06 | 52 | 3822 | 168341 | 63316807 |
| Anaesthetic complication neurological | 41.69 | 36.06 | 8 | 3866 | 256 | 63484892 |
| Epidural haemorrhage | 40.66 | 36.06 | 7 | 3867 | 120 | 63485028 |
| Anaphylactic reaction | 40.51 | 36.06 | 33 | 3841 | 66067 | 63419081 |
| Myelitis transverse | 38.77 | 36.06 | 10 | 3864 | 1250 | 63483898 |
| Brain stem syndrome | 37.79 | 36.06 | 8 | 3866 | 422 | 63484726 |
| Apnoea | 36.85 | 36.06 | 15 | 3859 | 8007 | 63477141 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 113.79 | 34.94 | 42 | 2292 | 15899 | 34938698 |
| Anaesthetic complication | 103.23 | 34.94 | 22 | 2312 | 1098 | 34953499 |
| Negative pressure pulmonary oedema | 81.29 | 34.94 | 14 | 2320 | 219 | 34954378 |
| Cardiac arrest | 78.89 | 34.94 | 59 | 2275 | 96100 | 34858497 |
| Local anaesthetic systemic toxicity | 64.40 | 34.94 | 12 | 2322 | 298 | 34954299 |
| Urethral valves | 58.96 | 34.94 | 11 | 2323 | 275 | 34954322 |
| Delayed recovery from anaesthesia | 58.50 | 34.94 | 13 | 2321 | 788 | 34953809 |
| Respiratory depression | 51.52 | 34.94 | 24 | 2310 | 16221 | 34938376 |
| Incorrect route of product administration | 47.28 | 34.94 | 22 | 2312 | 14823 | 34939774 |
| Phrenic nerve paralysis | 47.01 | 34.94 | 8 | 2326 | 116 | 34954481 |
| Bradycardia | 46.12 | 34.94 | 39 | 2295 | 75379 | 34879218 |
| Spinal cord infarction | 45.92 | 34.94 | 9 | 2325 | 294 | 34954303 |
| Hyperthermia malignant | 45.60 | 34.94 | 13 | 2321 | 2164 | 34952433 |
| Stress cardiomyopathy | 41.80 | 34.94 | 12 | 2322 | 2047 | 34952550 |
| Neuromuscular block prolonged | 41.41 | 34.94 | 9 | 2325 | 492 | 34954105 |
| Recurrence of neuromuscular blockade | 36.03 | 34.94 | 7 | 2327 | 218 | 34954379 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaesthetic complication | 227.58 | 27.28 | 51 | 6037 | 2808 | 79735492 |
| Anaphylactic shock | 223.88 | 27.28 | 89 | 5999 | 35907 | 79702393 |
| Maternal exposure during delivery | 169.28 | 27.28 | 35 | 6053 | 1311 | 79736989 |
| Cardiac arrest | 157.29 | 27.28 | 119 | 5969 | 171977 | 79566323 |
| Local anaesthetic systemic toxicity | 136.00 | 27.28 | 28 | 6060 | 1026 | 79737274 |
| Generalised tonic-clonic seizure | 131.37 | 27.28 | 65 | 6023 | 43845 | 79694455 |
| Cauda equina syndrome | 122.47 | 27.28 | 27 | 6061 | 1376 | 79736924 |
| Phrenic nerve paralysis | 106.32 | 27.28 | 19 | 6069 | 322 | 79737978 |
| Maternal exposure during pregnancy | 93.86 | 27.28 | 80 | 6008 | 136458 | 79601842 |
| Hypotension | 89.99 | 27.28 | 137 | 5951 | 440180 | 79298120 |
| Respiratory depression | 88.88 | 27.28 | 43 | 6045 | 27587 | 79710713 |
| Exposure during pregnancy | 87.96 | 27.28 | 68 | 6020 | 101064 | 79637236 |
| Neurotoxicity | 79.40 | 27.28 | 42 | 6046 | 32476 | 79705824 |
| Negative pressure pulmonary oedema | 79.09 | 27.28 | 14 | 6074 | 224 | 79738076 |
| Myoclonus | 76.95 | 27.28 | 39 | 6049 | 27621 | 79710679 |
| Monoplegia | 76.91 | 27.28 | 23 | 6065 | 3948 | 79734352 |
| Incorrect route of product administration | 76.58 | 27.28 | 42 | 6046 | 34887 | 79703413 |
| Peripheral nerve injury | 74.99 | 27.28 | 16 | 6072 | 698 | 79737602 |
| Anaphylactic reaction | 74.31 | 27.28 | 57 | 6031 | 83686 | 79654614 |
| Seizure | 73.60 | 27.28 | 81 | 6007 | 188753 | 79549547 |
| Bradycardia | 68.76 | 27.28 | 67 | 6021 | 135490 | 79602810 |
| Paraplegia | 67.38 | 27.28 | 22 | 6066 | 5031 | 79733269 |
| Ventricular fibrillation | 66.18 | 27.28 | 37 | 6051 | 31889 | 79706411 |
| Stress cardiomyopathy | 63.77 | 27.28 | 26 | 6062 | 11140 | 79727160 |
| Delayed recovery from anaesthesia | 61.44 | 27.28 | 16 | 6072 | 1657 | 79736643 |
| Motor dysfunction | 59.99 | 27.28 | 27 | 6061 | 14706 | 79723594 |
| Spinal cord paralysis | 58.01 | 27.28 | 10 | 6078 | 136 | 79738164 |
| Toxicity to various agents | 56.65 | 27.28 | 109 | 5979 | 421431 | 79316869 |
| Tracheal deviation | 55.87 | 27.28 | 10 | 6078 | 171 | 79738129 |
| Tachycardia | 55.40 | 27.28 | 68 | 6020 | 177700 | 79560600 |
| Circulatory collapse | 48.05 | 27.28 | 32 | 6056 | 37636 | 79700664 |
| Tonic clonic movements | 47.71 | 27.28 | 14 | 6074 | 2250 | 79736050 |
| Nerve block | 47.46 | 27.28 | 11 | 6077 | 702 | 79737598 |
| Diarrhoea | 47.03 | 27.28 | 6 | 6082 | 880483 | 78857817 |
| Product packaging confusion | 46.18 | 27.28 | 9 | 6079 | 248 | 79738052 |
| Hyperaesthesia | 45.36 | 27.28 | 21 | 6067 | 12201 | 79726099 |
| Paraparesis | 44.48 | 27.28 | 15 | 6073 | 3788 | 79734512 |
| Spinal epidural haemorrhage | 44.20 | 27.28 | 8 | 6080 | 146 | 79738154 |
| Respiratory arrest | 44.20 | 27.28 | 36 | 6052 | 57514 | 79680786 |
| Premature delivery | 42.73 | 27.28 | 25 | 6063 | 23442 | 79714858 |
| Hypoaesthesia | 42.52 | 27.28 | 60 | 6028 | 179292 | 79559008 |
| Vitamin K deficiency | 41.99 | 27.28 | 10 | 6078 | 718 | 79737582 |
| Caesarean section | 41.78 | 27.28 | 20 | 6068 | 12515 | 79725785 |
| Epidural haemorrhage | 41.14 | 27.28 | 8 | 6080 | 218 | 79738082 |
| Paralysis | 40.83 | 27.28 | 20 | 6068 | 13157 | 79725143 |
| Hyperthermia malignant | 40.11 | 27.28 | 13 | 6075 | 2904 | 79735396 |
| Fatigue | 39.77 | 27.28 | 11 | 6077 | 929716 | 78808584 |
| Type I hypersensitivity | 38.58 | 27.28 | 14 | 6074 | 4384 | 79733916 |
| Neuromuscular block prolonged | 38.54 | 27.28 | 10 | 6078 | 1020 | 79737280 |
| Spinal cord infarction | 38.24 | 27.28 | 9 | 6079 | 614 | 79737686 |
| Wrong product administered | 38.23 | 27.28 | 17 | 6071 | 8995 | 79729305 |
| Diplegia | 37.34 | 27.28 | 11 | 6077 | 1792 | 79736508 |
| Apnoea | 36.97 | 27.28 | 18 | 6070 | 11686 | 79726614 |
| Foetal heart rate abnormal | 36.91 | 27.28 | 8 | 6080 | 376 | 79737924 |
| Spinal anaesthesia | 35.90 | 27.28 | 6 | 6082 | 67 | 79738233 |
| Altered state of consciousness | 34.88 | 27.28 | 28 | 6060 | 43794 | 79694506 |
| Uterine hypotonus | 34.64 | 27.28 | 6 | 6082 | 84 | 79738216 |
| Diaphragmatic paralysis | 33.06 | 27.28 | 9 | 6079 | 1103 | 79737197 |
| Anaesthetic complication neurological | 32.79 | 27.28 | 8 | 6080 | 636 | 79737664 |
| Loss of consciousness | 32.36 | 27.28 | 51 | 6037 | 167892 | 79570408 |
| Myelitis transverse | 32.25 | 27.28 | 10 | 6078 | 1937 | 79736363 |
| Post procedural complication | 32.22 | 27.28 | 21 | 6067 | 23808 | 79714492 |
| Anterior spinal artery syndrome | 31.91 | 27.28 | 6 | 6082 | 136 | 79738164 |
| Oliguria | 31.35 | 27.28 | 18 | 6070 | 16291 | 79722009 |
| Epidural analgesia | 30.42 | 27.28 | 5 | 6083 | 50 | 79738250 |
| Oxygen saturation decreased | 30.30 | 27.28 | 43 | 6045 | 129004 | 79609296 |
| Product administration error | 28.92 | 27.28 | 22 | 6066 | 31824 | 79706476 |
| Tachypnoea | 28.79 | 27.28 | 22 | 6066 | 32041 | 79706259 |
| Arthralgia | 27.94 | 27.28 | 5 | 6083 | 571798 | 79166502 |
| Nervous system disorder | 27.63 | 27.28 | 20 | 6068 | 26836 | 79711464 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N01BB09 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Amides |
| FDA CS | M0000897 | Amides |
| MeSH PA | D000777 | Anesthetics |
| MeSH PA | D000779 | Anesthetics, Local |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:36333 | local anesthetics |
| FDA EPC | N0000175682 | Amide Local Anesthetic |
| FDA PE | N0000175976 | Local Anesthesia |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anesthesia for cesarean section | indication | 4847005 | |
| Local anesthesia | indication | 386761002 | |
| Regional Anesthesia for Labor Pain | indication | ||
| Major Nerve Block for Surgery | indication | ||
| Regional Anesthesia for Postoperative Pain | indication | ||
| Regional Anesthesia for Surgery | indication | ||
| Alcoholism | contraindication | 7200002 | |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Decreased cardiac function | contraindication | 43650005 | |
| Bradycardia | contraindication | 48867003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Urethral stricture | contraindication | 76618002 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Injury of head | contraindication | 82271004 | |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Disorder of biliary tract | contraindication | 105997008 | DOID:9741 |
| Procedure on urinary system | contraindication | 118677009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Lesion of brain | contraindication | 301766008 | |
| Deficiency of cholinesterase | contraindication | 360607009 | |
| Acute exacerbation of asthma | contraindication | 708038006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.24 | acidic |
| pKa2 | 7.84 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 5 subunit alpha | Ion channel | BLOCKER | IC50 | 4.56 | IUPHAR | CHEMBL | |||
| Sodium channel protein type 1 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 2 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 3 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 4 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 8 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 9 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 10 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Potassium channel subfamily K member 3 | Ion channel | IC50 | 4.28 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024055 | VUID |
| N0000022060 | NUI |
| D08490 | KEGG_DRUG |
| 132112-35-7 | SECONDARY_CAS_RN |
| 4021017 | VANDF |
| 4024055 | VANDF |
| C0073571 | UMLSCUI |
| CHEBI:8890 | CHEBI |
| CHEMBL1077896 | ChEMBL_ID |
| DB00296 | DRUGBANK_ID |
| CHEMBL1889140 | ChEMBL_ID |
| D000077212 | MESH_DESCRIPTOR_UI |
| 175805 | PUBCHEM_CID |
| 7602 | IUPHAR_LIGAND_ID |
| 5376 | INN_ID |
| 7IO5LYA57N | UNII |
| 1298851 | RXNORM |
| 19197 | MMSL |
| 43154 | MMSL |
| 5435 | MMSL |
| d04051 | MMSL |
| 006248 | NDDF |
| 006249 | NDDF |
| 109094008 | SNOMEDCT_US |
| 334196006 | SNOMEDCT_US |
| 386969005 | SNOMEDCT_US |
| 725651008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9263 | INJECTION | 2 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9263 | INJECTION | 2 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9263 | INJECTION | 2 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9264 | INJECTION | 5 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9264 | INJECTION | 5 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9264 | INJECTION | 5 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9265 | INJECTION | 7.50 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9265 | INJECTION | 7.50 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9265 | INJECTION | 7.50 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9266 | INJECTION | 10 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9266 | INJECTION | 10 mg | EPIDURAL | ANDA | 30 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9266 | INJECTION | 10 mg | EPIDURAL | ANDA | 30 sections |
| NAROPIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9924 | INJECTION, SOLUTION | 5 mg | INFILTRATION | NDA | 12 sections |
| NAROPIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9924 | INJECTION, SOLUTION | 5 mg | INFILTRATION | NDA | 12 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9300 | INJECTION, SOLUTION | 2 mg | INFILTRATION | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9300 | INJECTION, SOLUTION | 2 mg | INFILTRATION | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9301 | INJECTION, SOLUTION | 5 mg | EPIDURAL | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9301 | INJECTION, SOLUTION | 5 mg | EPIDURAL | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9302 | INJECTION, SOLUTION | 7.50 mg | EPIDURAL | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9302 | INJECTION, SOLUTION | 7.50 mg | EPIDURAL | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9303 | INJECTION, SOLUTION | 10 mg | EPIDURAL | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-9303 | INJECTION, SOLUTION | 10 mg | EPIDURAL | ANDA | 28 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3140 | INJECTION, SOLUTION | 5 mg | PARENTERAL | ANDA | 21 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3142 | INJECTION, SOLUTION | 10 mg | PARENTERAL | ANDA | 21 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-081 | INJECTION, SOLUTION | 5 mg | EPIDURAL | ANDA | 25 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-081 | INJECTION, SOLUTION | 5 mg | EPIDURAL | ANDA | 25 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-082 | INJECTION, SOLUTION | 2 mg | INFILTRATION | ANDA | 24 sections |
| Ropivacaine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-082 | INJECTION, SOLUTION | 2 mg | INFILTRATION | ANDA | 24 sections |
| ropivacaine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-652 | INJECTION, SOLUTION | 5 mg | EPIDURAL | ANDA | 34 sections |
| ropivacaine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-652 | INJECTION, SOLUTION | 5 mg | EPIDURAL | ANDA | 34 sections |